Erudio Healtherudio.com
Sponsor
RemeGen trials: what clinicians said in public
No HCP commentary report on a trial sponsored by RemeGen yet. Erudio has found public clinician commentary on 4 clinical trials sponsored by RemeGen: NCT06038396, RC48-C005, RC48-C009 and RC48-C016. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (RemeGen Co., Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RC48-C016 NCT05302284 · RemeGen Co., Ltd. DeepView → | first-line HER2-expressing advanced urothelial carcinoma | Phase 3 | Deep | View | |||
| RC48-C005 NCT03507166 · RemeGen Co., Ltd. FocusedView → | HER2-positive locally advanced or metastatic urothelial carcinoma | Phase 2 | Focused | View | |||
| RC48-C009 NCT03809013 · RemeGen Co., Ltd. FocusedView → | HER2-overexpressing locally advanced or metastatic urothelial cancer | Phase 2 | Focused | View | |||
| NCT06038396 NCT06038396 · RemeGen Co., Ltd. FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||